Your browser is no longer supported. Please, upgrade your browser.
RPRX Repros Therapeutics Inc. monthly Stock Chart
RPRX [NASD]
Repros Therapeutics Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.45% Shs Outstand25.25M Perf Week6.56%
Market Cap49.24M Forward P/E- EPS next Y-0.61 Insider Trans-2.82% Shs Float25.25M Perf Month29.14%
Income-19.60M PEG- EPS next Q-0.17 Inst Own27.50% Short Float3.10% Perf Quarter0.00%
Sales- P/S- EPS this Y13.50% Inst Trans18.36% Short Ratio2.87 Perf Half Y-1.52%
Book/sh0.34 P/B5.74 EPS next Y15.30% ROA-127.70% Target Price5.25 Perf Year23.42%
Cash/sh0.42 P/C4.69 EPS next 5Y27.90% ROE-151.50% 52W Range0.80 - 3.48 Perf YTD61.16%
Dividend- P/FCF- EPS past 5Y-15.20% ROI- 52W High-46.17% Beta-0.82
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low134.15% ATR0.12
Employees24 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)51.60 Volatility5.20% 7.01%
OptionableYes Debt/Eq0.00 EPS Q/Q37.30% Profit Margin- Rel Volume0.66 Prev Close1.95
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume272.13K Price1.87
Recom1.50 SMA202.58% SMA50-0.31% SMA2004.55% Volume89,807 Change-3.94%
Nov-16-16Upgrade Ladenburg Thalmann Neutral → Buy
Oct-30-15Downgrade BofA/Merrill Neutral → Underperform
May-14-13Reiterated Ascendiant Capital Markets Strong Buy $19 → $23
Mar-28-13Reiterated Ladenburg Thalmann Buy $18 → $25
Nov-15-12Reiterated Ascendiant Capital Markets Strong Buy $12 → $18
Oct-09-12Reiterated Ladenburg Thalmann Buy $15 → $18
Apr-10-12Initiated Ascendiant Capital Markets Strong Buy $6
Mar-16-11Reiterated Ladenburg Thalmann Buy $6 → $9
Dec-05-16 01:05PM  10 Major Pharma and FDA Catalysts Coming in December at 24/7 Wall St. +10.17%
Nov-17-16 01:04PM  REPROS THERAPEUTICS INC. Financials
Nov-16-16 07:01AM  Repros Therapeutics upgraded by Ladenburg Thalmann
Nov-15-16 04:45PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
07:39AM  Repros (RPRX) Reports Positive Top-Line Data on Proellex
Nov-14-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids GlobeNewswire
Nov-09-16 03:32PM  Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus +10.90%
11:11AM  REPROS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 04:06PM  Repros Therapeutics reports 3Q loss
04:01PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:00PM  Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-03-16 06:27PM  What to Expect from Repros (RPRX) This Earnings Season
Oct-10-16 09:20AM  Repros' Secondary Hypogonadism Drug under Review in EU
Oct-05-16 10:42AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure +5.80%
10:35AM  Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities GlobeNewswire
Sep-27-16 01:03PM  Repros Therapeutics, Inc. :RPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 27, 2016
Sep-26-16 09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:15AM  FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism GlobeNewswire
Sep-13-16 09:50AM  Repros Seeks EU Approval for Secondary Hypogonadism Drug
Sep-12-16 04:08PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
11:45AM  Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism GlobeNewswire
Sep-08-16 02:13PM  Why Twitter, AMD and 2 Other Stocks Are in the Red Today, While Repros is Surging at Insider Monkey +9.47%
01:19PM  Heres What Latest Data Could Mean For Repros Therapeutics Inc (RPRX) at Insider Monkey
12:50PM  Why Repros Is Rising
08:56AM  Repros Therapeutics' (RPRX) Proellex Positive in Phase II
Sep-07-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis GlobeNewswire
Aug-18-16 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Aug-16-16 10:39AM  Repros Presents 6-Month Interim Data on Enclomiphene -5.70%
Aug-15-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events
04:01PM  Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men GlobeNewswire
Aug-10-16 07:38AM  Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Aug-09-16 04:24PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:22AM  Repros Therapeutics reports 2Q loss
09:15AM  Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-04-16 08:45AM  Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
Jul-29-16 06:59AM  8 Stocks Under $10 to Trade for Huge Profits +17.78%
Jul-19-16 04:12PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure +16.57%
Jul-01-16 05:19PM  5 Top Biotech Performers of 2016
04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-24-16 08:54AM  Research Report Initiated on Select Biotechnology Equities -7.65%
Jun-07-16 01:44PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Jun-02-16 04:08PM  6 Biotechs Seriously on the Move at 24/7 Wall St. +18.34%
Jun-01-16 04:23PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.65%
04:01PM  Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men GlobeNewswire
May-18-16 04:18PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:01PM  Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids GlobeNewswire
May-16-16 04:56PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:00PM  Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board GlobeNewswire
May-11-16 09:01AM  Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
May-10-16 09:19AM  Repros Therapeutics reports 1Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
09:15AM  Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results GlobeNewswire
May-04-16 08:56AM  Will Repros Therapeutics (RPRX) Continue to Surge Higher? Zacks
May-03-16 09:25AM  Repros (RPRX) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-19-16 10:05AM  These Four Biotech Stocks Are Trading With Massive Volume Today Accesswire +12.19%
Apr-18-16 02:26PM  Why Disney (DIS), Amedica (AMDA), Cvent (CVT), UniPixel (UNXL), and Repros Therapeutics (RPRX) Are Spiking Today at Insider Monkey +22.91%
12:35PM  Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday Accesswire
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
Apr-14-16 03:01PM  Repros to drop testosterone drug in U.S. if key study fails +18.67%
12:07PM  Trending Stocks: Thursday's Top Trading Stock Investors Have Followed Accesswire
11:38AM  Whats the Deal With These 5 Stocks on the Move Today? at Insider Monkey
09:47AM  Repros Therapeutics given time to rally
08:30AM  4 Small Cap Stocks That Have To Be On Your Watchlist Today Accesswire
Apr-13-16 01:27PM  Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3 Accesswire +174.39%
12:30PM  Repros Reveals Positive Data on Proellex for Uterine Fibroids
10:49AM  These Small Cap Stocks Are Getting Big Time Attention Today Accesswire
Apr-12-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.75%
04:01PM  Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids GlobeNewswire
Mar-16-16 05:05PM  Repros Gives EU Update on Secondary Hypogonadism Drug
Mar-15-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.73%
04:01PM  Repros Announces Initiation of Formal Approval Process by the European Medicines Agency GlobeNewswire
09:40AM  Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up
Mar-14-16 09:33AM  Repros Therapeutics reports 4Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
09:15AM  Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results GlobeNewswire
Feb-17-16 02:40PM  Repros Updates on Proof-of-Concept Study on Enclomiphene +8.14%
11:40AM  LPCN: Encouraging Top-Line Results from PK Dose Finding Study of LPCN 1107; Raising Price Target
Feb-16-16 04:03PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:01PM  Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
Feb-09-16 04:30PM  Repros, FDA Meet to Discuss Issues of Enclomiphene's CRL
Feb-08-16 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -12.62%
04:01PM  Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism GlobeNewswire
Jan-19-16 11:22AM  Smart Money Highlights Oversold Stocks in Small Cap Biotechs Accesswire -6.06%
Jan-11-16 09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:15AM  Repros Announces Court of Appeals Affirmation of Summary Judgment in Favor of the Company GlobeNewswire
Jan-06-16 04:21PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.51%
Jan-04-16 04:06PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.44%
04:05PM  Repros Updates Enclomiphene Program GlobeNewswire
Dec-22-15 04:25PM  Repros Provides Update on Proellex Program, Data by 3Q16
Dec-21-15 04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:05PM  Repros Updates Proellex® Program GlobeNewswire
Dec-09-15 01:50PM  Is Evolution Petroleum Corporation (EPM) Going to Burn These Hedge Funds? at Insider Monkey
Dec-03-15 09:30AM  The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Dec-02-15 04:25PM  Repros Hits 52-Week Low after Enclomiphene Receives CRL
02:09PM  Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Dec-01-15 01:42PM  Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results at TheStreet -27.50%
09:51AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:50AM  Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene GlobeNewswire
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes enclomiphene, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone levels due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Masterson Nola EDirectorNov 21Sale1.953,3056,4450Nov 23 04:07 PM
PODOLSKI JOSEPHPresident and CEOFeb 18Buy0.9310,0009,30087,422Feb 19 04:06 PM
Anderson KatherineChief Financial OfficerJan 27Buy1.0812,00012,96023,875Jan 28 04:12 PM
Wernicke J. F.Chief Medical OfficerJan 25Buy1.1110,00011,12610,000Jan 28 04:12 PM
PODOLSKI JOSEPHPresident and CEOJan 07Buy1.143,5003,99077,422Jan 07 04:44 PM
PODOLSKI JOSEPHPresident and CEOJan 06Buy1.208,1779,80473,922Jan 07 04:44 PM